Caza Health provides a compact bench‑top fluorescent microscope that captures high‑resolution, label‑free images of vaginal samples and uses AI algorithms to deliver quantitative microbiome profiles within minutes. The point‑of‑care system enables primary‑care physicians, OB‑GYNs, and women's health clinics to diagnose bacterial vaginosis and related conditions instantly, without sending specimens to external labs.
Funding
$249.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many women's health conditions, such as bacterial vaginosis and other microbiome-related disorders, lack rapid, affordable point‑of‑care diagnostic tools, leading to delayed treatment and limited access in primary care settings.
Solution
Caza Health offers an AI‑driven diagnostic platform that evaluates the vaginal microbiome using a proprietary fluorescent scanning microscope. The bench‑top device performs fast, high‑resolution imaging of vaginal samples and applies machine‑learning algorithms to generate accurate microbiome profiles within minutes. By delivering results at the point of care, clinicians can make immediate, evidence‑based decisions without sending specimens to external labs. The system is designed to be compact and cost‑effective, enabling deployment in a wide range of healthcare environments, from community clinics to women's health practices.
Target Audience
Primary customers are primary‑care physicians, obstetrician‑gynecologists, and women's health clinics seeking on‑site diagnostic tools for vaginal health assessment.
Features
- Compact bench‑top fluorescent scanning microscope with rapid scanning capability
- High‑quality, label‑free imaging of vaginal microbiome samples
- Integrated AI algorithms that analyze image data to produce quantitative microbiome assessments
- Turnaround time of minutes, providing results during the patient visit
- Affordable hardware design suitable for low‑resource clinical settings